14-day Premium Trial Subscription Sign Up For FreeGet Free

Dicerna Pharmaceuticals Stock Forecast NASDAQ:DRNA

Price Target and Analyst Ratings

Most Recent Rating

On August 11, 2021 "B. Riley" gave "$49.00 - $35.00" rating for DRNA. The price target was changed from $22.19 to 6.9%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-11 $49.00 - $35.00 Target Lowered by B. Riley $21.29 $22.19→6.9%
2021-08-10 $34.00 - $28.00 Target Lowered by Chardan Capital $22.19 $22.58→5.2%
2021-08-10 Downgraded by The Goldman Sachs Group $22.19 $22.19→6.9%
2021-08-09 $32.00 Downgraded by Citigroup $23.83 $27.25→28.1%
2021-08-06 $54.00 - $47.00 Target Lowered by SVB Leerink $27.25 $37.92+1.7%
2021-08-06 $32.00 Downgraded by Truist $27.25 $37.92+1.7%
2021-08-06 Downgraded by Cowen $27.25 $37.92+1.7%
2021-08-06 $32.00 Reiterated by Truist Securities $27.25 $37.92+1.7%
2021-08-06 $48.00 - $36.00 Target Lowered by The Goldman Sachs Group $27.25 $24.89→34.4%
2021-08-06 $42.00 - $38.00 Target Lowered by HC Wainwright $27.25 $24.13→36.4%
2021-08-06 $35.00 - $30.00 Target Lowered by Royal Bank of Canada $27.25 $24.13→36.4%
2021-08-06 $32.00 Downgraded by Truist Securities $27.25 $24.13→36.4%
2021-06-25 $40.00 - $49.00 Reiterated by B. Riley $37.49 $38.04+0.1%
2021-06-25 Buy Reiterated by B. Riley $37.49 $40.00 → $49.00
2021-06-23 Buy Target Raised by HC Wainwright $37.04 $40.00 → $42.00
2021-06-23 Buy Reiterated by HC Wainwright $37.04 $40.00 → $42.00
2021-04-22 Buy Initiated by The Goldman Sachs Group $28.86 $48.00
2021-04-19 Target Raised by Truist Securities $29.09 $35.00 → $45.00
2021-04-19 Target Raised by Truist $29.09 $35.00 → $45.00
2021-04-16 Buy Initiated by The Goldman Sachs Group $28.96 $48.00
2021-04-13 Outperform Target Lowered by SVB Leerink $26.83 $45.00 → $44.00
2021-03-08 Buy Target Raised by HC Wainwright $26.62 $35.00 → $40.00
2021-03-08 Buy Target Raised by Chardan Capital $26.62 $25.00 → $34.00
2021-03-02 Buy Target Raised by Chardan Capital $29.51 $25.00 → $34.00
2021-03-02 Buy Target Raised by HC Wainwright $29.51 $35.00 → $40.00
2021-03-01 Buy Target Raised by B. Riley $28.88 $37.00 → $40.00
2021-03-01 Buy Reiterated by B. Riley $28.88 $37.00 → $40.00
2021-01-11 Buy Target Raised by B. Riley $24.10 $30.00 → $37.00
2021-01-11 Buy Reiterated by B. Riley $24.10 $30.00 → $37.00
2020-11-25 Outperform Target Lowered by SVB Leerink $23.37 $48.00 → $45.00
2020-08-10 Buy Reiterated by B. Riley $20.58 $30.00
2020-08-07 Buy Target Raised by HC Wainwright $21.03 $32.00 → $35.00
2020-08-07 Buy - Outperform Target Raised by SVB Leerink $21.03 $43.00 → $46.00
2020-06-15 Buy Reiterated by B. Riley $21.61 $30.00
2020-05-13 Buy Reiterated by B. Riley $22.50 $30.00
2020-05-12 Outperform Initiated by Royal Bank of Canada $23.67
2020-05-11 Buy Target Raised by SunTrust Banks $24.35 $28.00 → $33.00
2020-05-08 Buy Reiterated by HC Wainwright $20.84 $32.00
2020-05-08 Buy Reiterated by Chardan Capital $20.84 $25.00
2020-04-08 Buy Reiterated by B. Riley $19.00 $30.00
2020-04-07 Outperform Target Raised by SVB Leerink $18.10 $35.00 → $38.00
2020-04-07 Buy Target Raised by HC Wainwright $18.10 $30.00 → $32.00

DRNA Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -48.92% during the next 3 months and, with a 90% probability hold a price between $5.69 and $13.03 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-23 $10.76 $17.94 $25.12
2021-09-24 $10.37 $17.55 $24.73
2021-09-27 $9.98 $17.16 $24.35
2021-09-28 $9.60 $16.78 $23.96
2021-09-29 $9.21 $16.39 $23.57
2021-09-30 $8.82 $16.00 $23.18
2021-10-01 $8.43 $15.61 $22.79
2021-10-04 $8.04 $15.23 $22.41
2021-10-05 $7.66 $14.84 $22.02
2021-10-06 $7.27 $14.45 $21.63
2021-10-07 $6.88 $14.06 $21.24
2021-10-08 $6.49 $13.67 $20.85
2021-10-11 $6.11 $13.29 $20.47
2021-10-12 $5.72 $12.90 $20.08
2021-10-13 $5.33 $12.51 $19.69
2021-10-14 $4.94 $12.12 $19.30
2021-10-15 $4.55 $11.73 $18.92
2021-10-18 $4.17 $11.35 $18.53
2021-10-19 $3.78 $10.96 $18.14
2021-10-20 $3.39 $10.57 $17.75
2021-10-21 $3.00 $10.18 $17.36
2021-10-22 $2.61 $9.80 $16.98
2021-10-25 $2.23 $9.41 $16.59
2021-10-26 $1.84 $9.02 $16.20
2021-10-27 $1.45 $8.63 $15.81
2021-10-28 $1.06 $8.24 $15.42
2021-10-29 $0.68 $7.86 $15.04
2021-11-01 $0.29 $7.47 $14.65
2021-11-02 $-0.10 $7.08 $14.26
2021-11-03 $-0.49 $6.69 $13.87

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT